🇺🇸 FDA
Pipeline program

Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)

RAY902CT

Phase 1 other active

Quick answer

Phase Ib Open Label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial) for Bullous pemphigoid, Behçet’s Syndrome, Dermatomyositis, Antiphospholipid syndrome, Immune-mediated necrotizing myopathy, Immune Thrombocytopenia is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Bullous pemphigoid, Behçet’s Syndrome, Dermatomyositis, Antiphospholipid syndrome, Immune-mediated necrotizing myopathy, Immune Thrombocytopenia
Phase
Phase 1
Modality
other
Status
active

Clinical trials